Investor's Business Daily on MSN
Biogen clears key benchmark, hitting 80-plus RS rating
Rating for BiogenBIIB jumped into a new percentile Monday, with an increase from 80 to 84.Please watch the video at Investors ...
Six companies, including Alnylam Pharmaceuticals and Seagate Technology, will join the Nasdaq 100 when the changes take effect later this month. The updates aim to keep the index aligned with the ...
Here are the top catalysts for the Nasdaq 100 Index and its ETFs, like QQQ and JEPQ, including the upcoming BoJ rate decision ...
With notable therapies from Biogen, Sarepta and MacroGenics failing to show efficacy in pivotal or confirmatory trials, experts question the use of biomarker evidence for approval while one former ...
Get insights on Biogen’s Leqembi sales outlook, clinical value, risks, and what new drug approvals may mean for investors.
Bitcoin hoarding giant Strategy clung to its place in the Nasdaq 100 on Friday, continuing its year-long stint in the ...
Strategy stock maintains Nasdaq 100 inclusion after rebalancing while MSCI reviews digital asset treasury companies. Decision ...
Bitcoin giant Strategy kept its spot in the Nasdaq 100 on Friday, holding its year-long run inside the index while debate ...
Walmart transferred to the Nasdaq too late to be eligible for the Nasdaq-100's annual reconstitution. Six companies will join the Nasdaq-100 later this month - but not Walmart, which switched its ...
First Patient Expected to be Dosed Next Week with Intranasal Foralumab PET Scan Shows Presence of Untreated Neuroinflammation ...
Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...
With the other premium services, you can dive deep into additional metrics, portfolios, commentary and information about Biotechnology stocks as well as other industrys. Choosing Which of the 4 Best ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results